Radioimmunoscintigraphy of colorectal carcinoma using technetium-99m-labeled, totally human monoclonal antibody 88BV59H21-2

Seza A. Gulec, Aldo N Serafini, Frederick L Moffat, Ruben D. Vargas-Cuba, George N Sfakianakis, Dido Franceschi, Virginia Z. Crichton, Ramaswamy Subramanian, Jerry L. Klein, Robert L. De Jager

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Radioimmunoscintigraphy (RIS) using human monoclonal antibodies offers the important clinical advantage of repeated imaging over murine monoclonal antibodies by eliminating the cross-species antibody response. This article reports a Phase I-II clinical trial with Tc-99m-labeled, totally human monoclonal antibody 88BV59H21-2 in patients with colorectal carcinoma. The study population consisted of 34 patients with colorectal cancer (20 men and 14 women; age range, 44-81 years). Patients were administered 5-10 mg antibody labeled with 21-41 mCi Tc-99m by the i.v. route and imaged at 3-10 and 16-24 h after infusion using planar and single-photon emission computed tomographic (CT) techniques. Pathological confirmation was obtained in 25 patients who underwent surgery. Human antihuman antibody (HAHA) titers were checked prior to and 1 and 3 months after the infusion. RIS with Tc-99m-labeled 88BV59H21-2 revealed a better detection rate in the abdomen-pelvis region compared with axial CT. The combined use of both modalities increased the sensitivity in both the liver and abdomen-pelvis regions. Ten patients developed mild adverse reactions (chills and fever). No HAHA response was detected in this series. Tc-99m-labeled human monoclonal antibody 88BV59H21-2 RIS shows promise as a useful diagnostic modality in patients with colorectal cancer. RIS alone or in combination with CT is more sensitive than CT in detecting tumor within the abdomen and pelvis. Repeated RIS studies may be possible, due to the lack of a HAHA response.

Original languageEnglish
JournalCancer Research
Volume55
Issue number23 SUPPL.
StatePublished - Dec 1 1995

Fingerprint

Radioimmunodetection
Technetium
Colorectal Neoplasms
Monoclonal Antibodies
Pelvis
Abdomen
Antibody Formation
Chills
Phase II Clinical Trials
Clinical Trials, Phase I
Antibodies
Photons
Fever
Liver
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Radioimmunoscintigraphy of colorectal carcinoma using technetium-99m-labeled, totally human monoclonal antibody 88BV59H21-2. / Gulec, Seza A.; Serafini, Aldo N; Moffat, Frederick L; Vargas-Cuba, Ruben D.; Sfakianakis, George N; Franceschi, Dido; Crichton, Virginia Z.; Subramanian, Ramaswamy; Klein, Jerry L.; De Jager, Robert L.

In: Cancer Research, Vol. 55, No. 23 SUPPL., 01.12.1995.

Research output: Contribution to journalArticle

Gulec, SA, Serafini, AN, Moffat, FL, Vargas-Cuba, RD, Sfakianakis, GN, Franceschi, D, Crichton, VZ, Subramanian, R, Klein, JL & De Jager, RL 1995, 'Radioimmunoscintigraphy of colorectal carcinoma using technetium-99m-labeled, totally human monoclonal antibody 88BV59H21-2', Cancer Research, vol. 55, no. 23 SUPPL..
Gulec, Seza A. ; Serafini, Aldo N ; Moffat, Frederick L ; Vargas-Cuba, Ruben D. ; Sfakianakis, George N ; Franceschi, Dido ; Crichton, Virginia Z. ; Subramanian, Ramaswamy ; Klein, Jerry L. ; De Jager, Robert L. / Radioimmunoscintigraphy of colorectal carcinoma using technetium-99m-labeled, totally human monoclonal antibody 88BV59H21-2. In: Cancer Research. 1995 ; Vol. 55, No. 23 SUPPL.
@article{059362ad84f94805a4f87127dc655831,
title = "Radioimmunoscintigraphy of colorectal carcinoma using technetium-99m-labeled, totally human monoclonal antibody 88BV59H21-2",
abstract = "Radioimmunoscintigraphy (RIS) using human monoclonal antibodies offers the important clinical advantage of repeated imaging over murine monoclonal antibodies by eliminating the cross-species antibody response. This article reports a Phase I-II clinical trial with Tc-99m-labeled, totally human monoclonal antibody 88BV59H21-2 in patients with colorectal carcinoma. The study population consisted of 34 patients with colorectal cancer (20 men and 14 women; age range, 44-81 years). Patients were administered 5-10 mg antibody labeled with 21-41 mCi Tc-99m by the i.v. route and imaged at 3-10 and 16-24 h after infusion using planar and single-photon emission computed tomographic (CT) techniques. Pathological confirmation was obtained in 25 patients who underwent surgery. Human antihuman antibody (HAHA) titers were checked prior to and 1 and 3 months after the infusion. RIS with Tc-99m-labeled 88BV59H21-2 revealed a better detection rate in the abdomen-pelvis region compared with axial CT. The combined use of both modalities increased the sensitivity in both the liver and abdomen-pelvis regions. Ten patients developed mild adverse reactions (chills and fever). No HAHA response was detected in this series. Tc-99m-labeled human monoclonal antibody 88BV59H21-2 RIS shows promise as a useful diagnostic modality in patients with colorectal cancer. RIS alone or in combination with CT is more sensitive than CT in detecting tumor within the abdomen and pelvis. Repeated RIS studies may be possible, due to the lack of a HAHA response.",
author = "Gulec, {Seza A.} and Serafini, {Aldo N} and Moffat, {Frederick L} and Vargas-Cuba, {Ruben D.} and Sfakianakis, {George N} and Dido Franceschi and Crichton, {Virginia Z.} and Ramaswamy Subramanian and Klein, {Jerry L.} and {De Jager}, {Robert L.}",
year = "1995",
month = "12",
day = "1",
language = "English",
volume = "55",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "23 SUPPL.",

}

TY - JOUR

T1 - Radioimmunoscintigraphy of colorectal carcinoma using technetium-99m-labeled, totally human monoclonal antibody 88BV59H21-2

AU - Gulec, Seza A.

AU - Serafini, Aldo N

AU - Moffat, Frederick L

AU - Vargas-Cuba, Ruben D.

AU - Sfakianakis, George N

AU - Franceschi, Dido

AU - Crichton, Virginia Z.

AU - Subramanian, Ramaswamy

AU - Klein, Jerry L.

AU - De Jager, Robert L.

PY - 1995/12/1

Y1 - 1995/12/1

N2 - Radioimmunoscintigraphy (RIS) using human monoclonal antibodies offers the important clinical advantage of repeated imaging over murine monoclonal antibodies by eliminating the cross-species antibody response. This article reports a Phase I-II clinical trial with Tc-99m-labeled, totally human monoclonal antibody 88BV59H21-2 in patients with colorectal carcinoma. The study population consisted of 34 patients with colorectal cancer (20 men and 14 women; age range, 44-81 years). Patients were administered 5-10 mg antibody labeled with 21-41 mCi Tc-99m by the i.v. route and imaged at 3-10 and 16-24 h after infusion using planar and single-photon emission computed tomographic (CT) techniques. Pathological confirmation was obtained in 25 patients who underwent surgery. Human antihuman antibody (HAHA) titers were checked prior to and 1 and 3 months after the infusion. RIS with Tc-99m-labeled 88BV59H21-2 revealed a better detection rate in the abdomen-pelvis region compared with axial CT. The combined use of both modalities increased the sensitivity in both the liver and abdomen-pelvis regions. Ten patients developed mild adverse reactions (chills and fever). No HAHA response was detected in this series. Tc-99m-labeled human monoclonal antibody 88BV59H21-2 RIS shows promise as a useful diagnostic modality in patients with colorectal cancer. RIS alone or in combination with CT is more sensitive than CT in detecting tumor within the abdomen and pelvis. Repeated RIS studies may be possible, due to the lack of a HAHA response.

AB - Radioimmunoscintigraphy (RIS) using human monoclonal antibodies offers the important clinical advantage of repeated imaging over murine monoclonal antibodies by eliminating the cross-species antibody response. This article reports a Phase I-II clinical trial with Tc-99m-labeled, totally human monoclonal antibody 88BV59H21-2 in patients with colorectal carcinoma. The study population consisted of 34 patients with colorectal cancer (20 men and 14 women; age range, 44-81 years). Patients were administered 5-10 mg antibody labeled with 21-41 mCi Tc-99m by the i.v. route and imaged at 3-10 and 16-24 h after infusion using planar and single-photon emission computed tomographic (CT) techniques. Pathological confirmation was obtained in 25 patients who underwent surgery. Human antihuman antibody (HAHA) titers were checked prior to and 1 and 3 months after the infusion. RIS with Tc-99m-labeled 88BV59H21-2 revealed a better detection rate in the abdomen-pelvis region compared with axial CT. The combined use of both modalities increased the sensitivity in both the liver and abdomen-pelvis regions. Ten patients developed mild adverse reactions (chills and fever). No HAHA response was detected in this series. Tc-99m-labeled human monoclonal antibody 88BV59H21-2 RIS shows promise as a useful diagnostic modality in patients with colorectal cancer. RIS alone or in combination with CT is more sensitive than CT in detecting tumor within the abdomen and pelvis. Repeated RIS studies may be possible, due to the lack of a HAHA response.

UR - http://www.scopus.com/inward/record.url?scp=0028789351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028789351&partnerID=8YFLogxK

M3 - Article

VL - 55

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 23 SUPPL.

ER -